^
    2years
    A Phase 1/2a Study of a PI3Kδγ dual inhibitor ZX-101A in patients with advanced solid tumors (AACR 2022)
    Part 2 dose expansion will evaluate ZX-101A activity in up to three disease-specific cohorts. Inclusion of combination therapy is planned after obtaining the initial clinical assessment of ZX-101A on its safety, tolerability, pharmacokinetics, and pharmacodynamics in patients.
    Clinical • P1/2 data
    |
    PIK3CG (Phosphatidylinositol-4,5-Bisphosphate 3-Kinase Catalytic Subunit Gamma) • PIK3CD (Phosphatidylinositol-4 5-Bisphosphate 3-Kinase Catalytic Subunit Delta)
    |
    ZX-101A
    3years
    [VIRTUAL] A next-generation PI3Kδ/γ inhibitor, ZX-101A inhibiting solid tumor growth by enhancing anti-tumor immunity (AACR 2021)
    Its absorption, distribution, metabolism, and excretion (ADME) and safety profile, through a series of preclinical in vitro and in vivo studies, supported the ZX-101A clinical development. These results suggested ZX-101A as a potential immunotherapeutic agent to appropriate solid tumor types.
    PD(L)-1 Biomarker • IO biomarker
    |
    GLI2 (GLI Family Zinc Finger 2)
    |
    ZX-101A